With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...
Bangalore: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval ...
Every January, millions of people start the new year vowing to lose weight. But in 2025, many of those hoping to shed the ...
But you have to be sure you're giving the right dose for your dog's size. (Photo Credit: E+/Getty Images) Getting the dosage right is important because most Benadryl tablets are intended for humans.
While all state Medicaid programs include GLP-1s prescribed for Type 2 diabetes, only 36 states cover at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda).
AstraZeneca), liraglutide (Saxenda, Novo Nordisk), albiglutide (Tanzeum, GSK), dulaglutide (Trulicity, Lilly) and lixisenatide (Adlyxin, Sanofi) — have been linked to adverse GI events such as ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
depending on the dosage, before discounts or insurance, according to Novo Nordisk, which also sells a version of liraglutide approved for obesity, called Saxenda. “There are many people on this ...